Accelerated Partial Breast Irradiation using Stereotactic Body Radiation Therapy
Official title: Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT): a Multicenter, Observational Clinical Trial
Run by RPCR, Inc. · NCT04985032 · Data updated 2026-11-12
This study is testing a new type of targeted radiation treatment for women with certain types of breast cancer to see if it is safe and effective.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 100 Years |
| Sex | Women only |
| Enrollment | 200 (estimated) |
| Sponsor | RPCR, Inc. Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (Stuart, Florida and 1 other locations) |
| Status | Recruiting |
| Started | August 15, 2022 |
| Main results expected | August 15, 2024 |
| Study ends | June 2027 |
| Registry record updated | August 5, 2022 |
| Trial ID | NCT04985032 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 50 and older with low to intermediate grade ductal carcinoma in situ or invasive ductal carcinoma meeting specific tumor size and surgical margin criteria.
✕Probably not a fit
Patients with lobular histology, multiple disease foci, or those with prior breast cancer treatments are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry investigates the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using Stereotactic Body Radiation Therapy (SBRT) in women with ductal carcinoma in situ or invasive ductal carcinoma. The study aims to enroll 200 patients who will receive a total dose of 30 Gy over 5 treatment sessions, utilizing advanced imaging techniques for precise targeting. Participants will be followed for 5 years to assess outcomes and safety.
Why it matters
Potential benefit: If successful, this approach could provide a more effective and less invasive treatment option for early-stage breast cancer patients.
How similar studies have gone: Other studies utilizing stereotactic body radiation therapy for breast cancer have shown promising results, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Women 50 years or older 2. Low to intermediate grade DCIS or invasive ductal carcinoma 3. Tumor size \< 2 cm invasive ductal carcinoma and \< 2.5 cm DCIS 4. Well defined lumpectomy cavity on CT 5. Clear surgical ink margins \> 2mm for invasive cancer and \> 3 mm for DCIS 6. Node negative 7. Unifocal lesion 8. ER and/or PR positive 9. HER-2 negative 10. BRCA negative 11. Lumpectomy cavity must be \< 30% of whole breast volume Exclusion Criteria: 1. Lobular histology 2. Angiolymphatic invasion 3. Multiple foci of disease 4. Lymphovascular invasion 5. Active lupus or sarcoid 6. Distant metastases 7. Non-epithelial malignancies 8. Synchronous contralateral breast cancer 9. Grade 2 or higher oncoplastic surgery 10. Ipsilateral pacemaker 11. Ipsilateral breast implant 12. Neoadjuvant chemotherapy 13. Prior ipsilateral breast cancer or thoracic radiation 14. Poor breast integrity 15. Paget's Disease of the nipple 16. Pregnant patients 17. Severe cardiac, pulmonary, or liver diseases
Where it's running
-
CyberKnife Center of South Florida in Stuart
Stuart, Florida, United States Recruiting -
CyberKnife Centers of Tampa Bay
Tampa, Florida, United States Recruiting
Study contacts
- Study coordinator: Mark Perman, MD
- Email: Mark.Perman@usa.genesiscare.com
- Phone: 772-293-0377
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Partial Breast Radiation After Breast-Conserving Surgery Without Sentinel Node Biopsy
This pilot study tests whether partial breast irradiation is safe for women who had breast-conserving surgery without sentinel lymph node biopsy or axillary dissection.
-
How social factors relate to inflammation in women with breast cancer.
This pilot will try to link social and economic factors to blood markers of inflammation in women newly diagnosed with breast cancer who have not yet started treatment.
-
CAN1012 injection before surgery for DCIS or LCIS
A phase 1 study tests CAN1012 injected into the lesion of patients with DCIS or LCIS to see if it is safe before they have planned surgery.
-
Disappearing markers for daily breast radiation delivery
This trial will test whether Magic Ink tattoos are as safe and remain visible as standard tattoo ink for women getting radiation after breast cancer surgery.
-
Cavity marking technique to improve radiotherapy planning after breast-conserving oncoplastic surgery
This will test a new cavity-marking method to help radiation teams plan treatment more accurately for adults having breast-conserving surgery with oncoplastic reconstruction.
-
Radiation therapy for early-stage breast cancer using a shorter treatment schedule
This study is testing a shorter radiation treatment schedule for women 50 and older with early-stage breast cancer to see if it is safe and effective while reducing the number of visits needed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.